AbCellera Biologics Inc.ABCLNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank29
3Y CAGR-45.9%
5Y CAGR-42.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-45.9%/yr
Annual compound
5Y CAGR
-42.8%/yr
Recent deceleration
Percentile
P29
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 11.70% |
| 2024 | -4.78% |
| 2023 | 62.83% |
| 2022 | 73.82% |
| 2021 | 111.15% |
| 2020 | 190.65% |
| 2019 | 74.27% |
| 2018 | 0.00% |